Total trials
310
Active
44
Phase 3
26
Total enrollment
40,152
Pipeline matrix
Showing 27 of 27 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tranexamic Acid | — | — | — | — | — | 1 | |
| Itopride HCI 50 mg | — | — | — | — | — | 1 | |
| Metoclopramide 10 mg ampoule | — | — | — | — | — | 1 | |
| Vitamin D2 | — | — | — | — | — | 1 | |
| Calcitriol | — | — | — | — | — | 1 | |
| Empagliflozin 10 MG | — | — | — | — | 2 | ||
| Switching to low dose emicizumab | — | — | — | — | — | 1 | |
| Drospirenone | — | — | — | — | 2 | ||
| Transdermal Ethinyl Estradiol/Norelgestromin Patch | — | — | — | — | — | 1 | |
| Lemborexant 5 MG [Dayvigo] Period 1 | — | — | — | — | — | 1 | |
| Lemborexant 5 MG [Dayvigo] Period 2 | — | — | — | — | — | 1 | |
| Lemborexant 5 MG [Dayvigo] Period 3 | — | — | — | — | — | 1 | |
| Lemborexant 10 MG [Dayvigo] Period 1 | — | — | — | — | — | 1 | |
| Lemborexant 10 MG [Dayvigo] Period 2 | — | — | — | — | — | 1 | |
| Lemborexant 10 MG [Dayvigo] Period 3 | — | — | — | — | — | 1 | |
| Cabozantinib | — | — | — | — | — | 1 | |
| B7H3 specific CAR T cell with IL-7Ra signaling domain | — | — | — | — | — | 1 | |
| Mulberry Leaf Extract | — | — | — | — | — | 1 | |
| B7H3-IL7Ra CAR-T cells | — | — | — | — | — | 1 | |
| CD19-IL7Ra CAR-T cells | — | — | — | — | — | 1 | |
| Chimeric Antigen Receptor T Cells | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | — | 2 | ||
| Local PEG4000 | — | — | — | — | — | 1 | |
| Commercial PEG4000 | — | — | — | — | — | 1 | |
| Curcumin in Nanogels | — | — | — | — | — | 1 | |
| 0.1% Fluocinolone Acetonide Oral Paste | — | — | — | — | — | 1 | |
| urea 40% cream | — | — | — | — | — | 1 |
Next readouts
- 2024-06-01
- 2026-03-01
- 2026-03-01
- 2026-06-30
- 2026-06-30
- 2026-06-30
- 2026-07
- 2026-07
- 2026-07
- 2026-07-10
Top conditions
- Allergic Rhinitis10
- Acute Kidney Injury7
- Preterm Labor4
- Obesity4
- Sepsis4
- Septic Shock4
- Parkinson's Disease4
- Healthy4
Frequently asked questions about Chulalongkorn University
- How many clinical trials does Chulalongkorn University have on ClinicalTrials.gov?
- Chulalongkorn University is listed as the lead sponsor on 310 clinical trials in ClinicalTrials.gov, 44 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Chulalongkorn University's trials are in Phase 3?
- 26 of Chulalongkorn University's trials are in Phase 3, spread across 27 active drug programs.
- What therapeutic areas does Chulalongkorn University focus on?
- Chulalongkorn University's most-studied conditions on ClinicalTrials.gov are Allergic Rhinitis, Acute Kidney Injury, Preterm Labor, Obesity, Sepsis.
- When are Chulalongkorn University's next clinical trial readouts?
- Chulalongkorn University has 10 upcoming primary-completion readouts tracked here; the soonest is “The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors”, expected around 2024-06-01.